Philipp Lachenmann: DELPHI Rationale


“Young Investigator Fund” for Sofia-Iris Bibli

11.04.2018, Berlin | Hydrogen sulfide (H2S) has emerged as an important gaseous signaling molecule. Currently H2S donors have been proposed to affect angiogenesis, prevent atherosclerosis and limit cardiac infarct size. Endogenously, H2S is generated in the vascular wall during the metabolism of cysteine, through the action of cystathionine γ-lyase (CSE). The research project by the young scientist Dr. Sofia-Iris Bibli from Goethe University Frankfort tries to explore fundamental regulatory mechanisms of CSE-derived H2S and to apply them to paradigms of atherosclerosis development in vivo and extrapolate the results to human samples. Mechanistically, Dr. Bibli plans to identify the physiological relevance of protein sulfhydration- a post-translational protein modification mediated by H2S. The results of the project that focuses on mapping the impact of H2S on endothelial cell function and the human atherosclerotic plaque ‘sulfhydrome’ is expected to yield scientific breakthroughs relevant to both physiology/pathophysiology and H2S based pharmacotherapy. Dr. Bibli’s project is funded by a start-up grant of the Schering Stiftung as part of its program „BOOST – Young Investigator Fund for Innovative Research Ideas“.

Sofia-Iris Bibli

About Sofia-Iris Bibli

Sofia-Iris Bibli (born in Greece) obtained her MSc in Pharmacology in 2013 and earned her PhD with distinction in Molecular Pharmacology in 2016 from University of Athens. After completing her graduate training she was nominated two postdoctoral fellowships from the European Society of Cardiology (ESC Basic Research Fellowship 2016 and Research Grant 2016) and moved to the Institute for Vascular Signalling in Goethe University as a postdoctoral fellow, under the supervision of Prof. Ingrid Fleming. Her current projects aim to elucidate the role of cystathionine-γ-lyase derived hydrogen sulfide in endothelial cell homeostasis in health and disease.

About the funding program

The Schering Stiftung offers start-up grants to fund promising research ideas by young scientists. Support is provided for projects in the fields of biochemical, neuroscience or immunological basic research with biomedical implications that cannot be realized with existing funds and resources and for which application for other funding is not possible because of a lack of preliminary research. The start-up grant thus lays the foundations for a subsequent DFG or similar grant application. The program is explicitly aimed at highly motivated young investigators who want to become independent researchers and pursue their own research ideas. The Schering Stiftung has earmarked a total of EUR 120,000 for this grant program. In 2017, the foundation received more than 120 applications for the program. Two scientists were selected for funding.

The program will be continued this year in cooperation with the Fritz Thyssen Foundation. The call for applications will be published in the next weeks.


Founded in 2002 by Schering AG, Berlin, the independent and non-profit Ernst Schering Foundation aims to promote science and art ...